Skip to main content


Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study

Fig. 1

Weekly PEG-IFN adherence among HCV genotype 2/3 participants on shortened (12 weeks; n = 61; panel a) and standard therapy (24 weeks; n = 26; panel b). Each row represents a study participant. Dark green boxes represent a full prescribed dose was received, light green boxes represent an adjusted dose was received, and white boxes represent a missed dose

Back to article page